Skip to content

Satiety Response of Short Chain Fructooligosaccharide

Satiety Response of Short Chain Fructooligosaccharide

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01100788
Enrollment
20
Registered
2010-04-09
Start date
2009-03-31
Completion date
2009-06-30
Last updated
2010-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

Populations that report high fiber consumption demonstrate lower rates of obesity. Enhanced satiety may play a key role in this relationship. The colonic fermentation of fibers is theorized to influence satiety and food intake. Short chain fructooligosaccharide (scFOS) are rapidly fermentable fibers that can easily be added to foods to impact these parameters. The objective of this study was to evaluate the satiety response of scFOS and its ability to decrease food intake.

Detailed description

Intervention study with fiber added to beverages and acute effects on satiety measured.

Interventions

DIETARY_SUPPLEMENTShort chain fructo-oligosaccharide (scFOS) 5 g

Dietary Supplement: scFOS 5 g Novel fiber administered in two 5 g doses--the first in a beverage and the second in a solid chew.

OTHERPlacebo

Treatment without scFOS fiber

DIETARY_SUPPLEMENTShort chain fructooligosaccharide (scFOS) 8 g

Novel fiber administered in two 8 g doses--the first in a beverage and the second in a solid chew.

Sponsors

University of Minnesota
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy men and women * Age 18-64 years * Non-smoking * Not taking medication * Non-dieting (weight stable in prior 3 months) * BMI 18-27 * English literacy

Exclusion criteria

* Do not regularly consume breakfast * Food allergies to ingredients found in study products * BMI \<18 or \>27 * Diagnosed cardiovascular, renal, or hepatic disease diabetes mellitus * Cancer in previous 5 years (except basal cell carcinoma of the skin) * Any gastrointestinal disease or condition * Recent bacterial infection (\< 3 months) * Recent or concurrent participation in an intervention research study * History of drug or alcohol abuse in prior 6 months * Use of lipid-lowering, anti-hypertensive, or anti-inflammatory steroid medication * Eating disorder * Vegetarians * People who eat more than approximately 15 grams of fiber per day * Women who are pregnant or lactating * Women with irregular menstrual cycles

Design outcomes

Primary

MeasureTime frameDescription
Satiety response using visual analogue scales0, 15, 30, 45, 60, 90, 120, 180, 240 minutes postprandiallySatiety response was measured using subjective perceptions of hunger, fullness, satisfaction, and prospective food intake evaluated by previously validated visual analogue scales (VAS).

Secondary

MeasureTime frameDescription
Ad libitum food intake240 minutes postprandially and over 24 hours
Breath hydrogen response0, 240 minutes
Gastrointestinal tolerance using visual analogue scales (VAS)24 hoursSubjective ratings of bloating, stool consistency, and flatulence on VAS. A stool count was also recorded.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026